These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 21546499

  • 1. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA.
    Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C.
    Haematologica; 2011 Aug; 96(8):1136-43. PubMed ID: 21546499
    [Abstract] [Full Text] [Related]

  • 2. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
    Récher C, Coiffier B, Haioun C, Molina TJ, Fermé C, Casasnovas O, Thiéblemont C, Bosly A, Laurent G, Morschhauser F, Ghesquières H, Jardin F, Bologna S, Fruchart C, Corront B, Gabarre J, Bonnet C, Janvier M, Canioni D, Jais JP, Salles G, Tilly H, Groupe d'Etude des Lymphomes de l'Adulte.
    Lancet; 2011 Nov 26; 378(9806):1858-67. PubMed ID: 22118442
    [Abstract] [Full Text] [Related]

  • 3. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
    Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C.
    Ann Oncol; 2013 Apr 26; 24(4):1032-7. PubMed ID: 23235801
    [Abstract] [Full Text] [Related]

  • 4. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H.
    J Clin Oncol; 2014 Dec 10; 32(35):3996-4003. PubMed ID: 25385729
    [Abstract] [Full Text] [Related]

  • 5. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
    Lancet Oncol; 2017 Aug 10; 18(8):1076-1088. PubMed ID: 28668386
    [Abstract] [Full Text] [Related]

  • 6. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma.
    Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C.
    Ann Oncol; 2009 Dec 10; 20(12):1985-92. PubMed ID: 19567453
    [Abstract] [Full Text] [Related]

  • 7. Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
    Lefrère F, Bastit-Barrau D, Hequet O, Bourin P, Mathieu-Nafissi S, Bohbot A, Tilly H, Salles G, Fermé C, Lapierre V, Fornecker L, Micléa JM, Isebaert L, Bologna S, Fitoussi O, Mounier N, Haioun C.
    Transfusion; 2013 Jan 10; 53(1):115-22. PubMed ID: 22563760
    [Abstract] [Full Text] [Related]

  • 8. Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas.
    El Sayed R, El Darsa H, Kort J, Al Chami F, Ibrahim A, Charafeddine M, Bazarbachi A, Abou Dalle I, El Cheikh J.
    Clin Lymphoma Myeloma Leuk; 2021 Oct 10; 21(10):711-719. PubMed ID: 34140260
    [Abstract] [Full Text] [Related]

  • 9. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
    Inano S, Iwasaki M, Iwamoto Y, Sueki Y, Fukunaga A, Yanagita S, Arima N.
    Int J Hematol; 2014 Feb 10; 99(2):162-8. PubMed ID: 24338743
    [Abstract] [Full Text] [Related]

  • 10. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
    Wang X, Xia B, Wang CY, Li MZ, Xu W, Yuan T, Tian C, Zhao HF, Yang HL, Zhao ZG, Wang XF, Wang YF, Yu Y, Zhang YZ.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Feb 14; 40(2):117-124. PubMed ID: 30831626
    [Abstract] [Full Text] [Related]

  • 11. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.
    Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F.
    Blood; 2017 Sep 14; 130(11):1315-1326. PubMed ID: 28701367
    [Abstract] [Full Text] [Related]

  • 12. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH, Kim JW, Jeon YW, Lee SE, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, Park CW, Cho SG.
    Korean J Intern Med; 2015 May 14; 30(3):362-71. PubMed ID: 25995667
    [Abstract] [Full Text] [Related]

  • 13. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients.
    Haioun C, Mounier N, Quesnel B, Morel P, Rieux C, Beaujean F, Marolleau JP, Belhadj K, Simon D, Gaulard PH, Lepage E, Gisselbrecht CH, Reyes F.
    Ann Oncol; 2001 Dec 14; 12(12):1749-55. PubMed ID: 11843254
    [Abstract] [Full Text] [Related]

  • 14. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
    Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH, Hoppe RT.
    Leuk Lymphoma; 2016 Dec 14; 57(3):604-8. PubMed ID: 26159046
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.
    Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.
    J Clin Oncol; 2016 Nov 20; 34(33):4015-4022. PubMed ID: 28199143
    [Abstract] [Full Text] [Related]

  • 18. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ, Australasian Leukaemia Lymphoma Group (ALLG).
    Haematologica; 2017 Feb 20; 102(2):356-363. PubMed ID: 28143954
    [Abstract] [Full Text] [Related]

  • 19. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH, Lee JJ, Kim WS, Lee WS, Do YR, Oh SY, Kim MK, Mun YC, Shin HJ, Kwak JY, Kang HJ, Won JH, Kwon JH, Park E, Suh C, Yang DH.
    Eur J Haematol; 2015 Jun 20; 94(6):504-10. PubMed ID: 25288018
    [Abstract] [Full Text] [Related]

  • 20. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.
    Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H.
    Cancer Sci; 2020 Oct 20; 111(10):3770-3779. PubMed ID: 32767806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.